Medidata Rave Omics Collaboration Uncovers Novel Insights for Rare Disease Research

NEW YORK--(BUSINESS WIRE)--The Castleman Disease Collaborative Network (CDCN) discovered new patient subgroups, based on previously unknown proteomic signatures, with Medidata’s Rave Omics, a machine learning-based solution. These discoveries provide novel insights into treatment response and potential new drug targets, highlighting the value of precision medicine.